window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook

    Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Nuclera extends Series C funding to $87M to advance antibody engineering

    Nuclera has extended its Series C funding to a total [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    PacBio HiFi adopted to study sudden unexplained death in childhood and advance precision therapies for rare diseases

    PacBio is supporting two research initiatives that use its HiFi [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain

    FDA clears IND amendment for automated manufacturing of Cabaletta’s rese-cel using Cellares platforms

    Cellares has secured FDA clearance of an IND amendment allowing [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bio‑Sourcing and Zerion Pharma collaborate on first oral HER2 monoclonal antibody

    Bio‑Sourcing and Zerion Pharma have joined forces to develop the [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    FairJourney Bio launches cryo-EM services from San Diego laboratories

    FairJourney Bio (FJBio) has expanded its portfolio with the launch [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Argobio-backed Enodia raises €20.7 million seed to advance small-molecule protein degradation platform

    Argobio Studio has announced the successful seed financing of Enodia [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    Trenchant BioSystems confirms AutoCell platform can cut CGT manufacturing to 2.5 days

    Trenchant BioSystems has released internal and external data confirming its [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    CERo reports early safety signals and platelet transfusion-free interval in Phase 1 AML trial

    CERo Therapeutics has reported early clinical findings from its ongoing [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    TECregen raises CHF 10m (EUR 10.7m) seed financing and appoints Dr Bo Rode Hansen as chairman

    TECregen, a biotechnology company focused on thymus regeneration, has completed [...]

    May 5, 2026
Previous789Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Olorofim meets primary endpoint in phase 3 OASIS aspergillosis study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Spot Biosystems reports early clinical evidence for non-viral dystrophin delivery in Duchenne muscular dystrophy
    Categories: Advanced Therapies, Drug Discovery & Development
  • Neurizon strengthens manufacturing base with Elanco supply deal for ALS asset
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top